Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics.

Details

Ressource 1Download: 32325731_BIB_C808540B20FA.pdf (1252.24 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_C808540B20FA
Type
Article: article from journal or magazin.
Collection
Publications
Title
Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics.
Journal
Cancers
Author(s)
Martín-Blázquez A., Jiménez-Luna C., Díaz C., Martínez-Galán J., Prados J., Vicente F., Melguizo C., Genilloud O., Pérez Del Palacio J., Caba O.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
18/04/2020
Peer-reviewed
Oui
Volume
12
Number
4
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection remains the only curative treatment. However, fewer than 20% of patients are candidates for surgery at the time of presentation. Hence, there is a critical need to identify diagnostic biomarkers with potential clinical utility in this pathology. In this context, metabolomics could be a powerful tool to search for new robust biomarkers. Comparative metabolomic profiling was performed in serum samples from 59 unresectable PDAC patients and 60 healthy controls. Samples were analyzed by using an untargeted metabolomics workflow based on liquid chromatography, coupled to high-resolution mass spectrometry in positive and negative electrospray ionization modes. Univariate and multivariate analysis allowed the identification of potential candidates that were significantly altered in PDAC patients. A panel of nine candidates yielded excellent diagnostic capacities. Pathway analysis revealed four altered pathways in our patients. This study shows the potential of liquid chromatography coupled to high-resolution mass spectrometry as a diagnostic tool for PDAC. Furthermore, it identified novel robust biomarkers with excellent diagnostic capacities.
Keywords
biomarker, diagnosis, metabolomics, pancreatic ductal adenocarcinoma, reverse-phase liquid chromatography
Pubmed
Web of science
Open Access
Yes
Create date
02/05/2020 15:42
Last modification date
07/08/2024 12:17
Usage data